[go: up one dir, main page]

WO2007133908A2 - Emploi de l'oléocanthal, principe irritant de l'huile d'olive, ainsi que de composés de structure et de fonction similaires - Google Patents

Emploi de l'oléocanthal, principe irritant de l'huile d'olive, ainsi que de composés de structure et de fonction similaires Download PDF

Info

Publication number
WO2007133908A2
WO2007133908A2 PCT/US2007/067393 US2007067393W WO2007133908A2 WO 2007133908 A2 WO2007133908 A2 WO 2007133908A2 US 2007067393 W US2007067393 W US 2007067393W WO 2007133908 A2 WO2007133908 A2 WO 2007133908A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
oleocanthal
cho
chch
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/067393
Other languages
English (en)
Other versions
WO2007133908A3 (fr
Inventor
Catherine Peyrot Des Gachons
Jeffrey B. Sperry
Bruce Bryant
Paul A. S. Breslin
Amos B. Smith, Iii
Gary K. Beauchamp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monell Chemical Senses Center
University of Pennsylvania Penn
Original Assignee
Monell Chemical Senses Center
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/017937 external-priority patent/WO2006122128A2/fr
Application filed by Monell Chemical Senses Center, University of Pennsylvania Penn filed Critical Monell Chemical Senses Center
Priority to US12/597,053 priority Critical patent/US8586632B2/en
Publication of WO2007133908A2 publication Critical patent/WO2007133908A2/fr
Anticipated expiration legal-status Critical
Publication of WO2007133908A3 publication Critical patent/WO2007133908A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B2/00—Preservation of foods or foodstuffs, in general
    • A23B2/70—Preservation of foods or foodstuffs, in general by treatment with chemicals
    • A23B2/725—Preservation of foods or foodstuffs, in general by treatment with chemicals in the form of liquids or solids
    • A23B2/729—Organic compounds; Microorganisms; Enzymes
    • A23B2/742—Organic compounds containing oxygen
    • A23B2/75—Organic compounds containing oxygen with doubly-bound oxygen
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/30—Artificial sweetening agents
    • A23L27/39—Addition of sweetness inhibitors
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/88—Taste or flavour enhancing agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated

Definitions

  • the invention relates to the active principal in olive oil, termed oleocanthal and related analogs, and methods of using oleocanthals in various formulations including, food additives, pharmaceuticals, cosmetics, animal repellants, and discovery tools for mammalian irritation receptor genes, gene products, alleles, splice variants, alternate transcripts and the like.
  • the invention provides the enantioselective total syntheses of both enantiomers of oleocanthal 1 (Figure 1), which not only confirms the structure, but also permits the assignment of absolute stereochemistry of the olive oil irritant.
  • the synthesis provides an effective route to both enantiomers for further biological/sensory evaluation. Studies demonstrate that the levorotary (-)- enantiomer of 1 ( Figure 1) is responsible for the organoleptic properties experienced with premium olive oils at back of the throat.
  • the invention therefore provides isolated and purified deacetoxydialdehydic ligstroside aglycone, which we term oleocanthal.
  • the invention also provides functional derivatives of oleocanthal having the general formula I:
  • Ri and R 4 are independently H or OR 5 ,
  • R 2 and R 3 are independently CHO, or COOR 5
  • R 5 is a H, C1-C5 alkyl, or a glycoside
  • X is O, NH or CH 2
  • the invention also provides analogs of oleocanthal having General Formula XII:
  • R is CH 3 , (CH 2 ) 2 C 6 H 4 -4-OH, (CH 2 ) 3 C 6 H 4 -4-OH, (CH 2 )C 6 H 4 -4-OH, (CH 2 ) 3 C 6 H 4 -4-X 1 , (CH 2 ) 3 C 6 H 5 , (CH 2 ) 3 C 6 H 4 -2-OH, (CH 2 ) 3 C 6 H 4 -3-OH, (CH 2 ) 3 C 6 H 3 -3,4-OH, or (CH 2 ) 4 CH 3 ;
  • X I is a halogen
  • Y is CHO or CH 2 OH
  • Z is CHO, CH 2 OH, or Z and Y are CHOH (where Z and Y are connected by a single C-C bond).
  • oleocanthals The compounds of Formula I and XII, including oleocanthal, are collectively referred to herein as “oleocanthals” or “oleocanthal analogs” or “oleocanthal derivatives.”
  • oleocanthal specifically refers to deacetoxydialdehydic ligstroside aglycone.
  • the invention provides methods of synthesizing the purified enantiomers of oleocanthal.
  • the invention further provides methods of using oleocanthals in various formulations including, food additives (e.g., flavor enhancers, sweetness inhibitors, spices, flavorings, and preservatives); pharmaceuticals (e.g., antioxidants, micro-G protein and associated kinase inhibitors, A ⁇ 42 inhibitors, presenilin modifiers, ⁇ -secretase inhibitors, nonsteroidal anti-inflammatories, anti-pyretics, cold and flu symptom relievers, Cox-1, Cox-2 inhibitors, Cox-3 inhibitors, lipoxygenase inhibitors, and wound healers); cosmetics; animal repellants; and discovery tools for mammalian irritation receptor genes, gene products, alleles, splice variants, alternate transcripts and the like.
  • food additives e.g., flavor enhancers, sweetness inhibitors, spices, flavorings, and preservatives
  • pharmaceuticals e.g., antioxidants, micro-G protein and associated kinase inhibitors, A ⁇
  • Figure 1 shows phenolic compounds (1-4), including the dialdehydic and aldehydic forms of ligstroside (5) and oleuropeine (6).
  • Figure 2 shows a graph of the irritation intensity of various olive oils plotted against their concentrations of oleocanthal.
  • Figure 3 shows the synthetic scheme of (-)-oleocanthal.
  • Figure 4 shows the synthetic scheme of (+)-oleocanthal.
  • Figure 5 shows the scheme of a Structure Activity Relationship (SAR) Study.
  • Figure 6 shows responses of oleocanthal (5 microM) and analog 13 (5 microM) on trigeminal neurons using ratiometric calcium imaging. Each trace represents one cell.
  • Figure 7 shows the overlapping 3-dimensional structures of oleocanthal and analog 13.
  • Figure 8 illustrates the percentage of trigeminal neurons sensitive to 5 micromolar oleocanthal (OC) responding to increasing concentrations of analog 13.
  • Figure 9 illustrates oleocanthal and 4-DHPEA-EDA formation during olive oil production by enzymatic and chemical degradation of their respective precursors ligstroside and oleuropein, two glucosylated secoiridoids abundantly synthesized in unripe olives.
  • Standard reference works setting forth the general principles of chemical synthesis are well known to those of skill in the art and include, for example, A.I. Vogel, VOGEL'S TEXTBOOK OF PRACTICAL ORGANIC CHEMISTRY (5TM EDITION) WILEY, N.Y. 1989; and ORGANIC SYNTHESES. 9 collective volumes; Index for vol. 1-8; Wiley, N.Y.
  • taste perception refers to a response (e.g., biochemical, behavioral) or sensitivity to a taste stimulus.
  • Taste stimulus refers to any compound that elicits, for example at the biochemical level (e.g., activation or inhibition of a taste receptor) or behavioral level (e.g., preference, indifference, or distaste), a taste response which would be perceived by a mammal as at least one of the five taste elements, including sweet, salty, sour, bitter, and umami.
  • “Taste perception” or “taste stimulus,” or variants thereof does not require, though it does include, transmission of a neural signal resulting in in vivo sensation of taste by a mammal. Modification of taste perception includes an alteration of (enhancement of, reduction to, or change to) a biochemical response, an ingestive response, a taste preference, or general behavior of a mammal in response to a compound.
  • Preferred acyl and thioacyl groups are lower alkanoyl and lower thioalkanoyl having from 1 to about 6 carbon atoms in the alkyl group, and all combinations and subcombinations of ranges therein.
  • Alkyl refers to a saturated aliphatic hydrocarbon group which may be straight or branched and having from 1 to about 20 carbon atoms in the chain, and all combinations and subcombinations of ranges therein. Preferred alkyl groups may be straight or branched and have from 1 to about 10 carbon atoms in the chain. Branched means that a lower alkyl group such as, for example, methyl, ethyl or propyl, is attached to a linear alkyl chain.
  • “Lower alkyl” refers to an alkyl group having from 1 to about 6 carbons, and all combinations and subcombinations of ranges therein.
  • Cycloalkyl refers to an aliphatic ring having from about 3 to about 10 carbon atoms in the ring, and all combinations and subcombinations of ranges therein. Preferred cycloalkyl groups have from about 4 to about 7 carbon atoms in the ring.
  • Alkylcarbamoyl and dialkylcarbamoyl means that the nitrogen of the carbamoyl is substituted by one or two alkyl groups, respectively.
  • Carboxyl refers to a COOH group.
  • Alkoxy refers to an alkyl-0 group in which "alkyl” is as previously described. Lower alkoxy groups are preferred. Exemplary alkoxy groups include, for example, methoxy, ethoxy, n-propoxy, i-propoxy and n-butoxy.
  • Alkoxyalkyl refers to an alkyl group, as previously described, substituted by an alkoxy group, as previously described.
  • Aryl refers to an aromatic carbocyclic radical containing from about 6 to about 10 carbons, and all combinations and subcombinations of ranges therein.
  • exemplary aryl groups include phenyl and naphthyl.
  • Aralkyl means an alkyl group substituted by an aryl radical.
  • Optionally substituted aralkyl and “optionally substituted aryl” means that the aryl group, or the aryl group of the aralkyl group, may be substituted with one or more substituents which include, for example, alkyl, alkoxy, amino, nitro, carboxy, carboalkoxy, cyano, alkyl amino, halo, hydroxy, hydroxyalkyl, mercaptyl, alkylmercaptyl, trihaloalkyl, carboxyalkyl or carbamoyl.
  • Carbalkoxy refers to a carboxyl substituent esterif ⁇ ed with an alcohol of the formula C n H 2n+ i0H, wherein n is from 1 to about 6.
  • Halogen refers to chlorine (chloro), fluorine (fluoro), bromine (bromo) or iodine (iodo). Preferred among the halogens (or halos) are fluorine (or fluoro) and chlorine (or chloro), and most preferably fluorine.
  • Heterocyclyl refers to a ring structure containing from about 4 to about 10 members in which one or more of the atoms in the ring is an element other than carbon, e.g., N, O or S. Heterocyclyl groups may be aromatic or non-aromatic, i.e., the rings may be saturated, partially unsaturated, or fully unsaturated.
  • Preferred heterocyclyl groups include, for example, pyridyl, pyridazinyl, pyrimidinyl, isoquinolinyl, quinolinyl, quinazolinyl, imidazolyl, pyrrolyl, furanyl, thienyl, thiazolyl, benzothiazolyl, piperidinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, and morphonlinyl groups.
  • Optionally substituted heterocyclyl means that the heterocyclyl group may be substituted by one or more substituents wherein the substituents include, for example, alkoxy, alkylamino, aryl, carbalkoxy, carbamoyl, cyano, halo, heterocyclyl, trihalomethyl, hydroxy, mercaptyl, alkylmercaptyl and nitro.
  • “Hydroxyalkyl” refers to an alkyl group substituted by a hydroxy group. Hydroxy lower alkyl groups are preferred. Exemplary preferred groups include, for example, hydroxymethyl, 2-hydroxyethyl, 2-hydroxypropyl and 3-hydroxypropyl.
  • Hydrogenation catalyst refers to any compounds known in the art of organic synthesis to facilitate the addition of hydrogen. Hydrogenation catalysts include, but are not limited to palladium on carbon, palladium hydroxide on carbon, palladium on calcium carbonate poisoned with lead, and platinum on carbon.
  • Sulfonating agent refers to any reagents known in the art of organic synthesis to react with an alcohol to provide a sulfonate ester. Examples include, but are not limited to methanesulfonyl chloride, methanesulfonic anhydride, trifluoromethane sulfonyl chloride, trifluoromethane sulfonic anhydride, benzene sulfonyl chloride, p-toluenesulfonyl chloride, a p- toluenesulfonyl anhydride.
  • “Sulfonate ester” includes groups which result when a sulfonating agent is reacted with an alcohol in the presence of an acid scavenger to give a compound of form -OA, wherein A is SO 2 R', with R' deriving from the sulfonating agent.
  • Reducing agent refers to any reagents known in the art of organic synthesis to reduce the oxidation state of a carbon atom, for example, by reducing a ketone to an alcohol.
  • Reducing agents include, but are not limited to hydride derivatives, such as borohydrides, including lithium borohydride and sodium borohydrides.
  • Methylating agent refers to any reagent known in the art of organic synthesis to donate a methyl group to an alcohol to form an ether.
  • Methylating agents include, but are not limited to methylhalides such as methyliodide, methylchloride, methylbromide, and dimethylsulfate.
  • Acid scavenger refers to any species known in the art of organic synthesis capable of accepting a proton without reacting with the starting material or product.
  • Concatenated refers to multi-step processes (i.e., processes containing two or more steps) wherein the steps may be performed in a substantially continuous or sequential manner, preferably without the necessity for interim isolation and/or purification of the intermediate compounds.
  • “Pharmaceutically acceptable” refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem complications commensurate with a reasonable benefit/risk ratio.
  • “Pharmaceutically acceptable salts” refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • the term "acid addition salt” refers to the corresponding salt derivative of a parent compound which has been prepared by the addition of an acid.
  • the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.
  • Certain acidic or basic compounds may exist as zwitterions. All forms of the compounds, including free acid, free base and zwitterions, are contemplated to be within the scope of the present invention.
  • suitable solvents may be readily selected by one skilled in the art of organic synthesis.
  • suitable solvents are solvents which are substantially non-reactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, i.e., temperatures which may range from the solvent's freezing temperature to the solvent's boiling temperature.
  • a given reaction may be carried out in one solvent or a mixture of more than one solvent.
  • suitable solvents for a particular work-up following the reaction may be selected.
  • Suitable solvents, as used herein may include, by way of example and without limitation, chlorinated solvents, hydrocarbon solvents, aromatic solvents, ether solvents, protic solvents, polar aprotic solvents, and mixtures thereof.
  • Suitable halogenated solvents include, but are not limited to carbon tetrachloride, bromodichloromethane, dibromochloromethane, bromoform, chloroform, bromochloromethane, dibromomethane, butyl chloride, dichloromethane, tetrachloroethylene, trichloroethylene, 1,1,1-trichloroethane, 1 , 1 ,2-trichloroethane, 1,1-dichloroethane, 2- chloropropane, hexafluorobenzene, 1,2,4-trichlorobenzene, o-dichlorobenzene, chlorobenzene, fluorobenzene, fluorotrichloromethane, chlorotrifluoromethane, bromotrifluoromethane, carbon tetrafluoride, dichlorofluoromethane, chlorodifluoromethane, trifluoromethane, 1 ,
  • Suitable hydrocarbon solvents include, but are not limited to alkane or aromatic solvents such as cyclohexane, pentane, hexane, toluene, cycloheptane, methylcyclohexane, heptane, ethylbenzene, m-, o-, or p-xylene, octane, indane, nonane, benzene, ethylbenzene, and m-, o-, or p-xylene.
  • alkane or aromatic solvents such as cyclohexane, pentane, hexane, toluene, cycloheptane, methylcyclohexane, heptane, ethylbenzene, m-, o-, or p-xylene, octane, indane, nonane, benzene, ethylbenzene,
  • Suitable ether solvents include, but are not limited to dimethoxymethane, tetrahydrofuran, 1,3-dioxane, 1,4-dioxane, furan, diethyl ether, ethylene glycol dimethyl ether, ethylene glycol diethyl ether, diethylene glycol dimethyl ether, diethylene glycol diethyl ether, triethylene glycol diisopropyl ether, anisole, or t-butyl methyl ether.
  • Suitable protic solvents include, but are not limited to water, methanol, ethanol, 2-nitroethanol, 2-fluoroethanol, 2,2,2-trifluoroethanol, ethylene glycol, 1-propanol, 2-propanol, 2-methoxyethanol, 1-butanol, 2-butanol, i-butyl alcohol, t-butyl alcohol, 2-ethoxyethanol, diethylene glycol, 1-, 2-, or 3- pentanol, neo-pentyl alcohol, t-pentyl alcohol, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, cyclohexanol, benzyl alcohol, phenol, and glycerol.
  • Suitable aprotic solvents include, but are not limited to dimethylformamide (DMF), dimethylacetamide (DMAC), l,3-dimethyl-3,4,5,6-tetrahydro-2(lH)-pyrimidinone (DMPU), l,3-dimethyl-2-imidazolidinone (DMI), N-methylpyrrolidinone (NMP), formamide, N-methylacetamide, N-methylformamide, acetonitrile (ACN), dimethylsulfoxide (DMSO), propionitrile, ethyl formate, methyl acetate, hexachloroacetone, acetone, ethyl methyl ketone, ethyl acetate, isopropyl acetate, t-butyl acetate, sulfolane, N,N-dimethylpropionamide, nitromethane, nitrobenzene, and hexamethylphosphoramide.
  • DMF dimethylformamide
  • substantially pure form means that the compounds prepared using the present processes may preferably be substantially devoid of organic impurities.
  • organic impurities refers to organic materials, compounds, etc. , other than the desired product, that may be typically associated with synthetic organic chemical transformations including, for example, unreacted starting reagents, unreacted intermediate compounds, and the like.
  • the present processes may provide compounds that are at least about 75% pure, as measured by standard analytical techniques such as, for example, HPLC.
  • the compounds prepared using the present processes may be at least about 80% pure, with a purity of at least about 85% being more preferred.
  • the compounds prepared using the present processes may be at least about 90% pure, with a purity of at least about 95% being more preferred. In particularly preferred embodiments, the compounds prepared using the present processes may be more than about 95% pure, with a purity of about 100% being especially preferred.
  • substituted chemical moieties include one or more substituents that replace hydrogen.
  • substituents include, for example, halo (e.g., F, Cl, Br, I), alkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl, heterocyclyl, hydroxyl (OH), nitro (NO 2 ), nitrosyl (NO), cyano (CN), cyanato (CNO), thiocyanato (SCN), amino (e.g., NH 2 , NHR', NR' 2 ), azido (N 3 ), carboxyl (COOH), C(O)R', OR', C(O)OR', NHC(O)R', aminocarbonyl, thiol, thiolato (SR'), sulfonic acid (SO 3 H), phosphonic acid (PO 3 H), SO 2 R', phosphino (PH 2 , PHR', PR' 2 ), si
  • Processes of the present invention may yield mixtures of diastereomers.
  • processes may, if desired, include a separation step to isolate diastereomers.
  • Methods for separation of diastereomers are well known in the art and include, for example, chiral column chromatography, HPLC, re-crystallization, or classical resolution methods involving selective reactivity.
  • asymmetric synthesis may be used to produce a specific diastereomer.
  • polynucleotide refers to a nucleic acid molecule and includes genomic DNA, cDNA, RNA, mRNA, mixed polymers, recombinant nucleic acids, fragments and variants thereof, and the like.
  • Polynucleotide fragments of the invention comprise at least 10, and preferably at least 12, 14, 16, 18, 20, 25, 30, 35, 40, 45, 50, 75, or 100 consecutive nucleotides of a reference polynucleotide.
  • the polynucleotides include sense and antisense strands.
  • the polynucleotides may be naturally occurring or non-naturally occurring polynucleotides.
  • a “synthesized polynucleotide” as used herein refers to polynucleotides produced by purely chemical, as opposed to enzymatic, methods. "Wholly” synthesized DNA sequences are therefore produced entirely by chemical means, and “partially” synthesized DNAs embrace those wherein only portions of the resulting DNA were produced by chemical means.
  • the polynucleotides of the invention may be single- or double-stranded.
  • the polynucleotides of the invention may be chemically modified and may contain non-natural or derivatized nucleotide bases as will be readily appreciated by those skilled in the art.
  • Such modifications include, for example, labels, methylation, substitution of one or more nucleotides with an analog, internucleotide modifications such as uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoramidates, carbamates, etc.), charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.), pendent moieties (e.g., polypeptides, etc.), intercalators (e.g., acridine, psoralen, etc.), chelators, alkylators, and modified linkages ⁇ e.g., alpha anomeric nucleic acids, etc.).
  • uncharged linkages e.g., methyl phosphonates, phosphotriesters, phosphoramidates, carbamates, etc.
  • charged linkages e.g., phosphorothioates, phosphorodithioates, etc.
  • pendent moieties
  • synthetic molecules that mimic polynucleotides in their ability to bind to a designated sequence via hydrogen bonding and other chemical interactions.
  • Such molecules are known in the art and include, for example, those in which peptide linkages substitute for phosphate linkages in the backbone of the molecule.
  • Recombinant nucleic acid is a nucleic acid generated by combination of two segments of nucleotide sequence.
  • the combination may be, for example, by chemical means or by genetic engineering.
  • polynucleotide amplification refers to a broad range of techniques for increasing the number of copies of specific polynucleotide sequences.
  • amplification of either or both strand(s) of the target nucleic acid comprises the use of one or more nucleic acid-modifying enzymes, such as a DNA polymerase, ligase, RNA polymerase, or RNA-dependent reverse transcriptase.
  • polynucleotide amplification examples include, but are not limited to, polymerase chain reaction (PCR), nucleic acid sequence based amplification (NASB), self-sustained sequence replication (3SR), strand displacement activation (SDA), ligase chain reaction, Q ⁇ replicase system, and the like.
  • PCR polymerase chain reaction
  • NNB nucleic acid sequence based amplification
  • SDA self-sustained sequence replication
  • SDA strand displacement activation
  • ligase chain reaction Q ⁇ replicase system, and the like.
  • a wide variety of alternative cloning and in vitro amplification methodologies are well known to those skilled in the art. Examples of these techniques are found in, for example, Berger et al, Guide to Molecular Cloning Techniques, METHODS IN ENZYMOLOGY 152, Academic Press, Inc., San Diego, CA (Berger), which is incorporated herein by reference in its entirety.
  • oligonucleotide refers to a series of linked nucleotide residues which has a sufficient number of bases to be used in a polymerase chain reaction (PCR). This short sequence is based on (or designed from) a genomic or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar, or complementary DNA or RNA in a particular cell or tissue. Oligonucleotides comprise portions of a nucleic acid sequence having at least about 10 nucleotides and as many as about 50 nucleotides, often about 12 or 15 to about 30 nucleotides. They are chemically synthesized and may be used as probes.
  • Primer pair refers to a set of primers including a 5' upstream primer that hybridizes with the 5 ' end of a target sequence to be amplified and a 3 ' downstream primer that hybridizes with the complement of the 3' end of the target sequence to be amplified.
  • probe refers to nucleic acid sequences of variable length, for example between at least about 10 and as many as about 8,500 nucleotides, depending on use. Probes are used in the detection of identical, similar, or complementary target nucleic acid sequences, which target sequences may be single- or double-stranded. Longer probes are usually obtained from a natural or recombinant source, are highly specific, and are much slower to hybridize than oligomers, or shorter probes. They may be single- or double-stranded and are carefully designed to have specificity in PCR, hybridization membrane-based, or ELISA-like technologies.
  • stringent hybridization conditions or “stringent conditions” refers to conditions under which a probe, primer, or oligonucleotide will hybridize to its target sequence, but to a minimal number of or no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences will hybridize with specificity to their proper complements at higher temperatures. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T m ) for the specific sequence at a defined ionic strength and pH. The T m is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium.
  • T m thermal melting point
  • Stringent temperature conditions will generally include temperatures in excess of 30°C, typically in excess of 37 0 C, and may be in excess of 45 0 C.
  • Stringent salt conditions will ordinarily be less than 1.0 M, typically less than 0.5 M, and may be less than 0.2 M.
  • stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30 0 C for short probes, primers, or oligonucleotides (e.g., 10 to 50 nucleotides) and at least about 60 0 C for longer probes, primers, or oligonucleotides.
  • Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.
  • antisense oligonucleotide refers to a nucleic acid molecule that is complementary to at least a portion of a target nucleotide sequence of interest and specifically hybridizes to the target nucleotide sequence under physiological conditions.
  • double stranded RNA or “dsRNA” as used herein refers to a double-stranded RNA molecule capable of RNA interference, including small interfering RNA (siRNA) (see for example, Bass (2001) Nature 411 :428-429; Elbashir et al. (2001) Nature, 411 :494-498).
  • the term “complementary” refers to Watson-Crick base pairing between nucleotide units of a nucleic acid molecule.
  • marker gene refers to a gene encoding a product that, when expressed, confers a phenotype at the physical, morphologic, or biochemical level on a transformed cell that is easily identifiable, either directly or indirectly, by standard techniques and includes, but is not limited to, genes encoding proteins that confer resistance to toxins or antibiotics such as ampicillin, neomycin, and methotrexate; genes encoding proteins that complement auxotrophic deficiencies; and genes encoding proteins that supply critical components not available from complex media.
  • marker genes include green fluorescent protein (GFP), red fluorescent protein (DsRed), alkaline phosphatase (AP), ⁇ - lactamase, chloramphenicol acetyltransferase (CAT), adenosine deaminase (ADA), aminoglycoside phosphotransferase (NEOr, G418r) dihydro folate reductase (DHFR), hygromycin-B-phosphotransferase (HPH), thymidine kinase (TK), lacZ (encoding ⁇ - galactosidase), ⁇ -lactamase, luciferase (luc), and xanthine guanine phosphoribosyltransferase (XGPRT).
  • GFP green fluorescent protein
  • DsRed red fluorescent protein
  • AP alkaline phosphatase
  • CAT chloramphenicol acetyltransferase
  • ADA adenosine
  • promoter refers to a regulatory element that regulates, controls, or drives expression of a nucleic acid molecule of interest and can be derived from sources such as from adenovirus, SV40, parvoviruses, vaccinia virus, cytomegalovirus, or mammalian genomic DNA.
  • suitable promoters include, but are not limited to, CMV, MSH2, trp, lac, phage, and TRNA promoters.
  • Suitable promoters that can be used in yeast include, but are not limited to, such constitutive promoters as 3-phosphoglycerate kinase and various other glycolytic enzyme gene promoters such as enolase or glyceraldehydes-3 -phosphate dehydrogenase, or such inducible promoters as the alcohol dehydrogenase 2 promoter or metallothionine promoter.
  • constitutive promoters as 3-phosphoglycerate kinase and various other glycolytic enzyme gene promoters such as enolase or glyceraldehydes-3 -phosphate dehydrogenase, or such inducible promoters as the alcohol dehydrogenase 2 promoter or metallothionine promoter.
  • additional promoters that can serve the function of directing the expression of a marker or reporter.
  • the list is merely meant to show examples of what can be used and is not meant to limit the invention.
  • operably linked refers to juxtaposition wherein the components are in a functional relationship.
  • a promoter is operably linked or connected to a coding sequence if it controls the transcription or expression of the sequence.
  • Polypeptide refers to a polymer of amino acids without referring to a specific length.
  • Polypeptides of the invention include peptide fragments, derivatives, and fusion proteins. Peptide fragments preferably have at least about 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, or 100 amino acids. Some peptide fragments of the invention are biologically active. Biological activities include immunogenicity, ligand binding, and activity associated with the reference peptide.
  • Immunogenic peptides and fragments of the invention generate an epitope-specific immune response, wherein "epitope” refers to an immunogenic determinant of a peptide and preferably contains at least three, five, eight, nine, ten, fifteen, twenty, thirty, forty, forty-five, or fifty amino acids. Some immunogenic peptides of the invention generate an immune response specific to that peptide. Polypeptides of the invention include naturally occurring and non- naturally occurring peptides.
  • modified polypeptides wherein examples of such modifications include glycosylation, acetylation, phosphorylation, carboxylation, ubiquitination, labeling, etc.), analogs (such as non-naturally occurring amino acids, substituted linkages, etc.), and functional mimetics.
  • methods for labeling polypeptides include radioactive isotopes such as 32 P or 35 S, ligands that bind to labeled antiligands (e.g., antibodies), fluorophores, chemiluminescent agents, enzymes, and antiligands.
  • amino acid denotes a molecule containing both an amino group and a carboxyl group.
  • the amino acids are ⁇ -, ⁇ -, ⁇ - or ⁇ - amino acids, including their stereoisomers and racemates.
  • L-amino acid denotes an ⁇ -amino acid having the L configuration around the ⁇ -carbon, that is, a carboxylic acid of general formula CH(COOH)(NH 2 )-(side chain), having the L-configuration.
  • D-amino acid similarly denotes a carboxylic acid of general formula CH(COOH)(NH2)-(side chain), having the D-configuration around the ⁇ -carbon.
  • Side chains of L-amino acids include naturally occurring and non-naturally occurring moieties.
  • Non-naturally occurring (i.e., unnatural) amino acid side chains are moieties that are used in place of naturally occurring amino acid side chains in, for example, amino acid analogs.
  • Amino acid substituents may be attached, for example, through their carbonyl groups through the oxygen or carbonyl carbon thereof, or through their amino groups, or through functionalities residing on their side chain portions.
  • amino acid sequences are presented in the amino (N) to carboxy (C) direction, from left to right.
  • the N-terminal ⁇ -amino group and the C-terminal ⁇ -carboxy groups are not depicted in the sequence.
  • the nucleotide sequences are presented by single strands only, in the 5 ' to 3 ' direction, from left to right. Nucleotides and amino acids are represented in the manner recommended by the IUPAC-IUB Biochemical Nomenclature Commission, or amino acids are represented by their three letters code designations.
  • binding means the physical or chemical interaction between two proteins or compounds or associated proteins or compounds or combinations thereof. Binding includes ionic, non-ionic, Hydrogen bonds, Van der Waals, hydrophobic interactions, etc.
  • the physical interaction, the binding can be either direct or indirect, indirect being through or due to the effects of another protein or compound. Direct binding refers to interactions that do not take place through or due to the effect of another protein or compound but instead are without other substantial chemical intermediates. Binding may be detected in many different manners. As a non-limiting example, the physical binding interaction between two molecules can be detected using a labeled compound. Other methods of detecting binding are well-known to those of skill in the art.
  • contacting means bringing together, either directly or indirectly, a compound into physical proximity to a molecule of interest. Contacting may occur, for example, in any number of buffers, salts, solutions, or in a cell or cell extract.
  • the terms “modulates” or “modifies” means an increase or decrease in the amount, quality, or effect of a particular activity or protein.
  • Modules refer to any inhibitory or activating molecules identified using in vitro and in vivo assays for, e.g. , agonists, antagonists, and their homologues, including fragments, variants, and mimetics, as defined herein, that exert substantially the same biological activity as the molecule.
  • Inhibitors” or “antagonists” are modulating compounds that reduce, decrease, block, prevent, delay activation, inactivate, desensitize, or downregulate the biological activity or expression of a molecule or pathway of interest.
  • “Inducers,” “activators,” or “agonists” are modulating compounds that increase, induce, stimulate, open, activate, facilitate, enhance activation, sensitize, or upregulate a molecule or pathway of interest.
  • the level of inhibition or upregulation of the expression or biological activity of a molecule or pathway of interest refers to a decrease (inhibition or downregulation) or increase (upregulation) of greater than about 50%, 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.
  • the inhibition or upregulation may be direct, i.e., operate on the molecule or pathway of interest itself, or indirect, i.e., operate on a molecule or pathway that affects the molecule or pathway of interest.
  • a "purified” or “substantially purified” polynucleotide or polypeptide is substantially separated from other cellular components that naturally accompany a native (or wild-type) nucleic acid or polypeptide and/or from other impurities (e.g., agarose gel).
  • a purified polypeptide or protein will comprise about 60% to more than 99% w/w of a sample, and may be about 90%, about 95%, or about 98% pure.
  • isolated refers to a molecule that has been removed from its native environment.
  • isolated nucleic acid molecules include, but are not limited to, recombinant DNA molecules contained in a vector, recombinant DNA molecules maintained in a heterologous host cell, partially or substantially purified nucleic acid molecules, and synthetic DNA or RNA molecules.
  • "About" as used herein refers to +/- 10% of the reference value.
  • variant nucleotide or amino acid sequences refer to homologues, including, for example, isoforms, species variants, allelic variants, and fragments of the sequence of interest.
  • homologues including, for example, isoforms, species variants, allelic variants, and fragments of the sequence of interest.
  • homologous nucleotide sequence or “homologous amino acid sequence,” or variations thereof, refers to sequences characterized by a relative identity, at the nucleotide level with respect to a reference sequence, or homology at the amino acid level, of at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 81%, at least about 82%, at least about 83%, at least about 84%, at least about 85%, preferably at least about 90%, at least about 95%, at least about 98%, or at least about 99%, and more preferably 100%, to a reference sequence, or portion or fragment thereof encoding or having a functional domain.
  • DNA and RNA molecules that can code for the same polypeptide as that encoded by a nucleotide sequence of interest.
  • the present invention contemplates those other DNA and RNA molecules which, on expression, encode a polypeptide encoded by the nucleic acid molecule of interest.
  • Amino acid "insertions,” “substitutions” or “deletions” are changes to or within an amino acid sequence.
  • the variation allowed in a particular amino acid sequence may be experimentally determined by producing the peptide synthetically or by systematically making insertions, deletions, or substitutions of nucleotides in the nucleic acid sequence using recombinant DNA techniques. Alterations of the naturally occurring amino acid sequence can be accomplished by any of a number of known techniques. For example, mutations can be introduced into the polynucleotide encoding a polypeptide at particular locations by procedures well known to the skilled artisan, such as oligonucleotide-directed mutagenesis.
  • a chemical variant of the present invention may exhibit substantially the biological activity of a naturally occurring oleocanthal, or have improved activity.
  • Biological activity refers to the level of a particular function (for example, antioxidant activity, anti-inflammatory activity, etc.) of a molecule or pathway of interest in a biological system.
  • Wild-type biological activity refers to the normal level of function of a molecule or pathway of interest.
  • Reduced biological activity refers to a decreased level of function of a molecule or pathway of interest relative to a reference level of biological activity of that molecule or pathway.
  • Increased biological activity refers to an increased level of function of a molecule or pathway of interest relative to a reference level of biological activity of that molecule or pathway.
  • increased biological activity may refer to an increased level of biological activity relative to the wild-type biological activity of a molecule or pathway of interest.
  • Reference to exhibiting "substantially the biological activity of naturally-occurring oleocanthal" indicates that variants within the scope of the invention can comprise substitutions, meaning that one or more chemical moieties of oleocanthal are replaced by different chemical moieties and such compounds retain the biological activity of oleocanthal, have substantially the same biological activities of oleocanthal, or have improved biological activity as compared to naturally-occurring oleocanthal.
  • a nucleotide and/or amino acid sequence of a nucleic acid molecule or polypeptide identified by the screening method of the invention may be used to search a nucleotide and amino acid sequence databank for regions of similarity using Gapped BLAST (Altschul, et al. (1997) Nucl. Acids Res. 25:3389). Briefly, the BLAST algorithm, which stands for Basic Local Alignment Search Tool is suitable for determining sequence similarity (Altschul, et al. (1990) J. MoI. Biol. 215:403-410). Software or performing BLAST analyses is publicly available through the National Center for Biotechnology Information.
  • This algorithm involves first identifying high scoring sequence pair (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence.
  • T is referred to as the neighborhood word score threshold (Altschul, et al. (1990) J. MoI. Biol. 215:403-410).
  • Extension for the word hits in each direction are halted when: (1) the cumulative alignment score falls off by the quantity X from its maximum achieved value; (2) the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or (3) the end of either sequence is reached.
  • the BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment.
  • BLAST algorithm Karlin, et al. (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877
  • Gapped BLAST perform a statistical analysis of the similarity between two sequences.
  • One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance.
  • P(N) the smallest sum probability
  • a nucleic acid is considered similar to a gene or cDNA if the smallest sum probability in comparison of the test nucleic acid to the reference nucleic acid is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.
  • Mimetics refers to a compound that is sterically similar to a reference compound. Mimetics are structural and functional equivalents to the reference compounds.
  • patient and “subject” are used interchangeably herein and include, but are not limited to amphibians, birds, dogs, cats, cattle, horses, buffalo, llama, sheep, goats, pigs, rodents, monkeys, apes, and humans.
  • "Host cell” includes, for example, prokaryotic cells, such as bacterial cells; eukaryotic cells, such as yeast cells and animal cells, including, but not limited to invertebrate cells (e.g., insect cells and nematode cells), amphibian cells (e.g., frog cells), particularly mammalian cells (e.g.
  • "Rodents” include, for example, rats and mice.
  • Mammalian cell lines available as hosts for expression are known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC), including but not limited to Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), NlE-115 (Liles et al, (1986) J. Biol. Chem. 261 :5307-5313), PC 12 human hepatocellular carcinoma cells (e.g., Hep G2).
  • ATCC American Type Culture Collection
  • treatment refers to any indicia of success of prevention, treatment, or amelioration of a disease or condition.
  • Treatment includes any objective or subjective parameter, such as, but not limited to, abatement, remission, normalization of receptor activity, reduction in the number or severity of symptoms or side effects, or slowing of the rate of degeneration or decline of the patient.
  • Treatment also includes a prevention of the onset of symptoms in a patient that may be at increased risk for or is suspected of having a disease or condition but does not yet experience or exhibit symptoms thereof.
  • the term "compound” means any identifiable chemical or molecule, including, but not limited to a small molecule, peptide, protein, sugar, nucleotide, or nucleic acid. Such compound can be natural or synthetic.
  • bitter refers to a basic taste characterized by solutions of such compounds as quinine, caffeine, and certain other alkaloids, that are sensed in humans primarily by taste buds at the back of the tongue, which are perceived as acrid, sharp, pungent, or harsh.
  • sweet refers to a basic taste characterized by solutions of sugars (e.g., sucrose and glucose), alcohols, glycols, some small molecules and some amino acids that are sensed in humans primarily by taste buds on the tip of the tongue, which are perceived as agreeable or pleasing.
  • sugars e.g., sucrose and glucose
  • alcohols e.g., alcohols, glycols, some small molecules and some amino acids that are sensed in humans primarily by taste buds on the tip of the tongue, which are perceived as agreeable or pleasing.
  • our refers to a basic taste characterized by solutions of vinegar and the juices of most unripe fruits and having a acid or sharp, tart, or biting taste.
  • Oleocanthals of the invention have the general formula I or XII.
  • Compounds of general formula I have the following structure:
  • Ri and R 4 are independently H or OR 5
  • R 2 and R 3 are independently CHO, or COOR 5
  • Compounds of general formula XII have the following structure:
  • R is CH 3 , (CH 2 ) 2 C 6 H 4 -4-OH, (CH 2 ) 3 C 6 H 4 -4-OH, (CH 2 )C 6 H 4 -4-OH, (CH 2 ) 3 C 6 H 4 -4-X 1 , (CH 2 ) 3 C 6 H 5 , (CH 2 ) 3 C 6 H 4 -2-OH, (CH 2 ) 3 C 6 H 4 -3-OH, (CH 2 ) 3 C 6 H 3 -3,4-OH, or (CH 2 ) 4 CH 3 ;
  • X I is a halogen
  • Y is CHO or CH 2 OH
  • Z is CHO, CH 2 OH, or Z and Y are CHOH (where Z and Y are connected by a single C-C bond).
  • Oleocanthal is specifically deacetoxydialdehydic ligstroside aglycone, which exists as a single isomer (enantiomer).
  • the (-)-enantiomer is the natural product and has the following chemical formula:
  • D-ribose may be converted to Formula I with a strong acid (e.g., hydrochloric acid) in acetone and methanol to yield Formula Ia.
  • a strong acid e.g., hydrochloric acid
  • the compound of Formula Ia may be treated with a halogenation reagent (e.g., iodine), phosphine (PPh 3 ) imidazole followed by metal halogen exchange (e.g., BuLi or Zn) induced ring opening to yield an aldehyde of Formula Ha.
  • a halogenation reagent e.g., iodine
  • metal halogen exchange e.g., BuLi or Zn
  • DCM dichloromethane
  • PCC pyridinium chlorochromate
  • the compound of Formula IVa is contacted with hydrogen, palladium in a suitable solvent (e.g., ethyl acetate (EtOAc)) to yield (-)-cyclopentanone (Formula Va).
  • a suitable solvent e.g., tetrahydrofuran
  • the (-)-cyclopentanone (Formula Va) is treated with lithium hexamethyldisilazide (LHMDS) followed by hexamethylphosphoramide (HMPA), dimethyl zinc and alkyl bromoacetate (e.g., methyl, ethyl, tert-butyl) to yield (-)-(3,4-dimethoxy-2-oxo-cyclopentyl)-acetic acid ester (Formula Via).
  • the compound of Formula Via is subjected to a Wittig ethylnation using ethyltriphenylphosphine bromide (or iodide) at reduced temperature, preferably -40 0 C or less.
  • D-ribose may be converted to Formula XI with a strong acid (e.g., hydrochloric acid) in acetone to yield Formula XI.
  • the compound of Formula XI may be treated with methyltriphenylphosphine bromide (or iodide) followed by oxidative cleavage of the diol to yield a compound of Formula lib.
  • (+)-cyclopentanone (Formula Vb) is treated with lithium hexamethyldisilazide (LHMDS) followed by hexamethyl phosphoramide (HMPA), dimethyl zinc and alkyl bromoacetate (eg., methyl, ethyl, tert-butyl) to yield (+)-(3,4-dimethoxy-2-oxo- cyclopentyl)-acetic acid ester (Formula VIb).
  • the compound of Formula VIb is subjected to a Wittig ethylnation using ethyltriphenylphosphine bromide (or iodide) at reduced temperature, preferably -40 0 C or less.
  • the ester is hydrolyzed (Formula VIIIb) and the compound of formula VIIIb is contacted with 4-hydroxyphenethyl alcohol in the presence of phosphine, dialkyl azodicarboxylate (e.g., diethyl or diisopropyl) (DEAD or DIAD) to give the Formula IXb.
  • phosphine, dialkyl azodicarboxylate e.g., diethyl or diisopropyl
  • DIAD diisopropyl
  • the invention contemplates mimetics of oleocanthal that have the general formula I or XII shown above.
  • Mimetics or mimics of oleocanthal may be designed for pharmaceutical use. Mimetics may be used in the same manner as oleocanthal, and hence are functional equivalents. The generation of a structural-functional equivalent may be achieved by the techniques of modeling and chemical design known to those of skill in the art. It will be understood that all such sterically similar constructs fall within the scope of the present invention.
  • the design of mimetics to a known pharmaceutically active compound is a known approach to the development of pharmaceuticals based on a "lead" compound. This is desirable where, for example, the active compound is difficult or expensive to synthesize, or where it is unsuitable for a particular method of administration, e.g., some peptides may be unsuitable active agents for oral compositions as they tend to be quickly degraded by proteases in the alimentary canal.
  • the active region of the compound has been identified, its structure is modeled according to its physical properties, e.g., stereochemistry, bonding, size, and/or charge, using data from a range of sources, such as, but not limited to, spectroscopic techniques, X-ray diffraction data, and NMR.
  • Computational analysis, similarity mapping (which models the charge and/or volume of the active region, rather than the bonding between atoms), and other techniques known to those of skill in the art can be used in this modeling process.
  • the three-dimensional structure of the compound is modeled.
  • a candidate general formula is selected onto which chemical groups that mimic oleocanthal can be grafted.
  • the general formula and the chemical groups grafted onto it can conveniently be selected so that the mimetic is easy to synthesize, is pharmacologically acceptable, and does not degrade in vivo, while retaining the biological activity of oleocanthal. Further optimization or modification can then be performed to arrive at one or more final mimetics for in vivo or clinical testing.
  • the oleocanthals of the invention provide the characteristic irritation sensation found in premium olive oils.
  • the oleocanthals may be added to lower grade oils to provide for an oil that tastes like premium extra virgin olive oil. As such, the oleocanthals act as a flavorant or flavor enhancer.
  • the oleocanthals and formulations of the invention may also be added to other foods to enhance the flavor or the food by providing a pleasing irritation sensation of olive oil.
  • the oleocanthals of the invention may be added to foods and oral pharmaceutical preparations and oral hygiene products such as toothpaste, mouthwash, breath- fresheners, films, candies, lozenges to provide an irritant for the oral product's sensory-irritation experience.
  • Oleocanthals may also provide sweetness inhibition, or allow the structural design of other sweetness inhibitors. Such sweetness inhibitors are useful when carbohydrates are added for bulking and altering food body and texture.
  • oleocanthals may be used to add an irritant to food for enhancing the flavor and gastronomic experience in a similar fashion to other spices such as chilis, mustards, onions, Szechwan pepper, and ginger, for example.
  • the oleocanthals and formulations of the invention may be added directly to food items to act as a preservative.
  • the food items may be for human consumption or animal consumption.
  • Especially preferred food items for the method of preservation are items which are customarily stored in oil.
  • a suitable and effective amount of one or more oleocanthals or a formulation thereof is added directly to the food item or oil in which the food item is stored.
  • the oleocanthals or formulation thereof is used to coat the food item prior to packaging.
  • the formulation may be sprayed onto the food item or the food item may be dipped in the formulation.
  • the oleocanthals or formulation thereof is applied to the inside surface of packaging material that is in contact with the food item to prevent spoilage.
  • the coating may be a thin film sprayed onto the inner surface or laminated onto the inner surface, for example.
  • the packaging material used to store the food item is impregnated with one or more oleocanthals or a formulation thereof.
  • the oleocanthals of this invention are usually administered in the form of pharmaceutical compositions.
  • These compounds can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal. These compounds are effective as both injectable and oral compositions.
  • Such compositions are prepared in a manner well known in the pharmaceutical art and comprise at least one active compound.
  • compositions which contain other active ingredients in addition to the one or more oleocanthals with pharmaceutically acceptable carriers.
  • the active ingredient is usually mixed with an excipient, diluted by an excipient or enclosed within such a carrier which can be in the form of a capsule, sachet, paper or other container.
  • the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient.
  • compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, 1-10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.
  • excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methyl cellulose.
  • the formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents.
  • the compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
  • compositions are preferably formulated in a unit dosage form, each dosage containing from about 0.001 to about 1 g, more usually about 1 to about 30 mg, of the active ingredient.
  • unit dosage forms refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
  • the compound of formula I or XII above is employed at about 20 weight percent of the pharmaceutical composition or less, more preferably about 15 weight percent or less, with the balance being pharmaceutically inert carrier(s).
  • the active compound is effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It, will be understood, however, that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered and its relative activity, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
  • the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention.
  • a solid preformulation composition containing a homogeneous mixture of a compound of the present invention.
  • the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
  • This solid preformulation is then subdivided into unit dosage forms of the type described above containing from, for example, 0.1 to about 500 mg of the active ingredient of the present invention.
  • the tablets or pills of the present invention may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
  • the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
  • the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release.
  • enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
  • compositions of the present invention may be formulated in sustained release form to provide the rate controlled release of any one or more of the components to optimize the therapeutic effects while minimizing undesirable side effects.
  • Suitable dosage forms for sustained release include layered tablets containing layers of varying disintegration rates or controlled release polymeric matrices impregnated with the active components and shaped in tablet form or capsules containing such impregnated or encapsulated porous polymeric matrices.
  • liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as corn oil, cottonseed oil, sesame oil, olive oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
  • aqueous solutions suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as corn oil, cottonseed oil, sesame oil, olive oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
  • compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
  • the liquid or solid compositions may contain suitable pharmaceutically acceptable carrier materials.
  • the compositions are administered by the oral or nasal respiratory route for local or systemic effect.
  • Compositions in preferably pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a face mask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices which deliver the formulation in an appropriate manner.
  • the oleocanthals of the invention may be used in a method for treating the symptoms of the cold or flu.
  • Formulations may be prepared containing oleocanthals as the active ingredient, or in combination with other active ingredients to be taken orally, rectally, intranasally or as an inhalant, for example.
  • the formulation comprising one or more oleocanthals may be in the form of a lollipop, quick-dissolving film, tablet, syrup, liquid, liqui-gel, capsule, or the like.
  • the amount of oleocanthals in the preparation may be adjusted by a physician of skill in the art for suitable dosages for adults or pediatric use, or by a veterinarian of skill in the art for use in various animals.
  • the dosage of drug may be determined based on the weight of the subject or based on surface area. Any method of determining proper dosages is acceptable.
  • the oleocanthals are preferably formulated with a pharmaceutically acceptable diluent, excipient or carrier (collectively referred to herein as "carrier” materials) as described above.
  • the oleocanthals of the invention are useful as counter-irritants for sore throat which may accompany a cold or flu, for example.
  • One or more oleocanthals may be applied in combination with other ingredients for sore throat relief or may be provided as the sole active ingredient.
  • the oleocanthal-based sore throat formulations may be in the form of a tablet, lozenge, lollipop, chewing gum, or throat spray. The formulation may be prepared and packaged by any means known in the art.
  • solid dosage forms may contain other ingredients known in such dosage forms such as acidity regulators, opacifiers, stabilizing agents, buffering agents, flavorings, sweeteners, coloring agents, and preservatives.
  • a lozenge may be prepared as by heating the lozenge base (e.g. , a mixture of sugar and liquid glucose) under a vacuum to remove excess water and the remaining components are then blended into the mixture. The resulting mixture is then drawn into desired shape. The lozenges are cooled, and packaged into suitable packaging. Lozenges will normally be sucked by the patient to release the oleocanthal or oleocanthal analog.
  • Chewable solid dose formulations may be made by the methods used to prepare chewable candy products or chewing gums.
  • a chewable solid dosage form may be prepared from an extruded mixture of sugar and glucose syrup to which the one or more oleocanthals has been added with optional addition of whipping agents, humectants, lubricants, flavors and colorings.
  • Spray formulations may be prepared by dissolving or suspending the one or more oleocanthals in a liquid medium which may also contain other ingredients such as stabilizing agents, buffering agents, flavorings, sweeteners, coloring agents, and preservatives.
  • a spray may be prepared by dissolving water soluble components in water and non- water soluble ingredients in a co-solvent (e.g., alcohol). The two phases are then mixed and the resulting mixture filtered and placed into dispensing containers.
  • the dispensing containers may be fitted with a metered, manually-operated spray mechanism or the dispenser may contain a pressurized propellant and be fitted with a suitable dispensing valve.
  • the oleocanthals of the invention are useful as a nasal decongestant.
  • the one or more oleocanthals may be applied in combination with other nasal decongestants or may be provided as the sole active ingredient.
  • the oleocanthal-based nasal formulations may be in the form of a lavage or nasal mist.
  • the formulation may be prepared and packaged by any means known in the art for nasal lavages and mists.
  • Oleocanthals are believed to have anti-oxidant activity and as such may be used to treat or prevent various conditions including cancer.
  • the oleocanthals may also be used to promote wound healing, either by application directly onto wounds, or as a coating or impregnation of bandages, sutures and the like.
  • the antioxidant effects of oleocanthals may also be exploited in the formulation of cosmetics.
  • the compositions can protective of skin or hair or as an anti-solar composition.
  • the compound of formula (I) or (XII), and preferably one or more oleocanthals is generally present in an amount ranging from 1 to 1,000 mg. In some embodiments, one or more oleocanthals are present in an amount of about 5 to 800 mg. In other embodiments, one or more oleocanthals are present in an amount of about 10 to 750 mg. In other embodiments, one or more oleocanthals are present in an amount of about 25 to 600 mg.
  • one or more oleocanthals are present in an amount of about 50 to 500 mg. In certain embodiments, one or more oleocanthals are present in 1, 5, 10, 20, 25, 50, 75, 100, 125, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 or 1,000 mg.
  • compositions according to the present invention acts as an antioxidant agent.
  • These compositions can be capillary compositions such as hair lacquers, hair setting lotions or hair treating or disentangling lotions, shampoos, coloring shampoos, hair dye compositions, makeup products such as nail enamels, skin treating creams and oils, foundations, lipsticks, compositions for the care of the skin such as bath oils or creams as well as any other cosmetic composition capable of exhibiting, because of their components, oxidation stability problems during storage.
  • the oleocanthals of the invention may be used as to treat and prevent pain.
  • the compounds are useful for the relief of pain associated with a variety of conditions including, but not limited to influenza or other viral infections, common cold, low back and neck pain, dysmenorrhea, headache, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis, degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis, burns, injuries, cancer and for pain associated with surgical and dental procedures.
  • the oleocanthals of the invention may be used as anti-inflammatory agents.
  • the oleocanthals may be used in a method for treating or preventing diseases marked by inflammation, including but not limited to psoriasis, cancer, asthma, allergic rhinitis, respiratory distress syndrome, inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome, ulcerative colitis, migraine, periarteritis nodosa, thyroiditis, aplastic anemia, Hodgkin's disease, scleroderma, type I diabetes, myasthenia gravis, multiple sclerosis, sorcoidosis, ischemic kidney disease, nephrotic syndrome, Bechet's syndrome, polymyositis, gingivitis, conjunctivitis, vascular disease myocardial ischemia, heart disease, stroke, and hypertension.
  • diseases marked by inflammation including but not limited to psoriasis, cancer, asthma, allergic rhinitis
  • the oleocanthals of the invention may also be formulated for treatment or prevention of the development of A ⁇ 42 associated Alzheimer's plaques and tangles in a manner similar to that found for non-steroidal anti-inflammatory drugs such as ibuprofen.
  • ibuprofen and oleocanthal inhibit micro-G proteins and associated kinases, for example Ras and Rock, which have been associated with the development of A ⁇ 42 associated plaques and tangles in the brains of Alzheimer's patients.
  • Oleocanthals also acts to inhibit ⁇ -secretases and alter presenilin conformations of which both activities are associated with reducing A ⁇ 42 associated Alzheimer's plaques and tangles.
  • APP A ⁇ amyloid precursor protein
  • oleocanthal may be used for the treatment and prevention of neurodegenerative disorders (e.g., Alzheimer's and other cognitive impairment associated with amyloid plaques and tangles).
  • the treatment and prevention of such neurodegenerative disorders may be performed using a racemic mixture of oleocanthal, or may be using one of the purified enantiomers of oleocanthal.
  • the oleocanthals of the present invention are also useful as treatments for use in conjunction with oral surgery and oral irradiation treatment of cancer. While not wishing to be bound by any particular theory of operation, it is believed that the oleocanthals, with their attendant anti-inflammatory activity, act to inhibit the inflammation that occurs in the oral cavity as a result of surgery or oral irradiation.
  • the oleocanthals may be formed as an oral rinse which can be administered before the procedure, after the procedure, or during the procedure, or a combination of these treatment regimens.
  • the amount of oleocanthal or oleocanthal analog in the rinse is a therapeutically effective amount which is readily determined by one of skill in the art.
  • oleocanthals with their organoleptic qualities, are useful as animal repellents.
  • the compounds may be used to repel carnivorous and omnivorous animals and birds, including domestic cats, rodents, raccoons, dogs, other canids such as coyotes.
  • the method of this invention comprises applying an effective, repellent amount of the oleocanthals, either alone or in combination with a suitable carrier, to the locus from which the animals are to be repelled.
  • suitable carriers would include liquid diluents such as water, hydrocarbons, alcohols, emulsif ⁇ ers and other liquids generally found in household spray formulations or pharmaceutical preparations so as to be acceptable from a human safety viewpoint.
  • Inert solid carriers such as starches may also be of use, and it might be desirable to incorporate the compounds into a controlled-release formulation.
  • the repellent compounds disclosed herein might be incorporated into various potentially-edible compositions which, if consumed, could injure or kill an animal.
  • An example of such a composition would be liquid antifreeze.
  • Another aspect of this invention provides methods for repelling birds from consuming or utilizing a material otherwise susceptible to consumption or utilization by birds, comprising providing to the material an avian repellent amount of at least one oleocanthal or oleocanthal analog.
  • Liquid carriers may be employed and the repellent may be sprayed on the material. See e.g., U.S. Pat. No. 2,967,128 which patent is incorporated by reference as if fully set forth herein.
  • the compound may be dispersed in the liquid from which the birds are to be repelled.
  • the repellent may be at least partially trapped in a solid vehicle to improve its persistency such as disclosed in U.S. Pat. No. 4,790,990.
  • the vehicle may be a modified starch, oil or polymer which at least partially encapsulates, emulsifies or substantially uniformly disperses the aversive agent.
  • the repellent compound and vehicle may be dispersed throughout solids consumed by avian species to reduce the likelihood that they will eat the treated edible.
  • Non-potable liquids such as industrial or agricultural waste water, mine tailing ponds, and freestanding water on artificial surfaces like airport runways and parking lots.
  • Non-potable refers to liquids or aquatic habitats wherein said liquid may be consumed or utilized by birds to the detriment of man or the birds.
  • oleocanthal Knowledge of the absolute structure of oleocanthal allows the identification of the oleocanthal receptor and related genes. Screening assays for receptors, well-known in the art, may be employed to determine the oleocanthal receptor. Tissue from the back of the throat, known to interact with oleocanthal may be isolated and subjected to various assays to determine the binding of oleocanthal to cells and the molecular signaling pathway of oleocanthals.
  • Labeled oleocanthal or oleocanthal analog may be used in tissue binding studies to determine the cell types that contain a presumptive oleocanthal receptor. Cells that have bound labeled oleocanthal or analog may be visualized by any method known in the art.
  • oleocanthal or an analog may be labeled with a radiolabel (e.g., 125 1, 35 S, 32 P, 33 P, 3 H), a fluorescence label, a chemiluminescent label, an enzymatic label, or an immunogenic label.
  • a radiolabel e.g., 125 1, 35 S, 32 P, 33 P, 3 H
  • a fluorescence label e.g., 125 1, 35 S, 32 P, 33 P, 3 H
  • a fluorescence label e.g., 125 1, 35 S, 32 P, 33 P, 3 H
  • luminescent or fluorescent molecules may be conjugated to the oleocanthal molecule.
  • the labeled oleocanthal or analog may be allowed to bind to cells in situ and visualized under a microsope.
  • cells in suspension may be labeled with the labeled oleocanthal or oleocanthal analog and labeled cells may be separated from unlabeled cells by flow cytometry or using a sorter, such as a fluorescence-activated cell sorter (FACS).
  • FACS fluorescence-activated cell sorter
  • a molecule is conjugated to oleocanthal or an oleocanthal analog that allows the conjugated oleocanthal or oleocanthal analog to be cross-linked to its receptor upon binding.
  • This may be performed by any means known in the art.
  • the cross-linked receptor may be isolated from the cells, purified and subjected to N-terminal amino acid sequencing.
  • degenerate oligonucleotides may be synthesized based on the possible combinations of oligonucleotides encoding the amino acid sequence and the oligonucleotides may be used in various ways to identify the gene encoding the oleocanthal receptor.
  • the degenerate oligonucleotides are used to probe gene libraries.
  • the gene library may a library formed from animal cells, particularly human cells, or it may be a specific cell-type library from animal cells known to be responsive to oleocanthal.
  • the library may be a subtractive library formed by removing commonly expressed genes from oleocanthal-responsive and oleocanthal- unresponsive cells, such that the library consists of a subset of genes reflecting unique sequences of the oleocanthal-responsive cells.
  • the degenerate oligonucleotides are paired with a second set of oligonucleotides to allow rt-PCR amplification of polynucleotides containing the sequences encoding the amino acid sequence of the oleocanthal receptor.
  • Such second set of oligonucleotides may include, for example, oligo-dT which anneals to poly- adenosine tracts of mRNA.
  • the rt-PCT reaction may be performed on RNA extracted from oleocanthal responsive cells. The methods and techniques for such genetic analysis are well- known in the art and may be found in the references and texts referred to herein.
  • (+)- and (-)-cyclopentanones were prepared via the sulfoximine and/or enzymatic protocols introduced and developed by Johnson (Johnson, CR. and T. Penning (1988) J. Am. Chem. Soc. 110:4726-4735; Johnson, CR. (1998) Ace. Chem. Res. 31:333-341). Although effective on modest scale (10-lOOmg), the requirement for gram quantities of the oleocanthals demanded that we secure for more scalable routes to (10). Towards this end, we optimized a hybrid of synthetic approaches (Moon, H. et al (2002) Tetrahedron: Asym. 13(11): 1189-1193; Jin, Y. et al.
  • This restricted throat irritation of oleocanthal is remarkably similar to that elicited by ibuprofen. Due to the observed organoleptic similarity, we isolated and then synthesized oleocanthal from olive oil. Sensory and chemical evaluation of 10 commercially available olive oils revealed a strong positive relationship between throat irritation intensity and oleocanthal concentration. Cyclooxygenase and lipoxygenase assays with synthesized oleocanthal demonstrated that it is a NSAID with an anti-inflammatory profile strikingly similar to that of ibuprofen, in accordance with its sensory properties. Oleocanthal may play a significant role in the well-known health benefits associated with a diet high in olive oil.
  • Retention information about the throat-irritating principal from the HPLC method allowed us to separate it from the majority of the other co-extracted phenolic compounds using methanol and water solvent mixtures at three different ratios of eluting solvents.
  • HPLC analysis of the throat irritating fraction revealed the presence of several unresolved compounds. A new HPLC gradient was thus developed and only one well-resolved peak was throat-irritating. A detailed NMR (ID and 2D) analysis was conducted with this material.
  • Olive oils differ markedly in their ability to elicit throat irritation. If oleocanthal is primarily responsible for this sensory property there should be a positive relation between compound concentration and degree of throat irritation. To test this hypothesis, we purchased 10 different olive oils with widely varying degrees of throat irritation based on informal evaluation. The amount of oleocanthal in each was then quantified. The compound was extracted from small amounts of each of the 10 oils (1 g) by hexane-acetonitrile (liquid- liquid) extraction. The solvent extract was analyzed by reverse-phase HPLC with UV detection at 278 nm. Oleocanthal was chromatographically separated from the other extracted compounds with an elution gradient of acetonitrile and water.
  • the degree of throat irritation of these 10 oils was quantified by 17 volunteers. Each subject was tested only 2 times per day with two different olive oils samples with 1-2 hours separating each test since the irritation may be sensitive to shorter inter-trial intervals. Subjects wore nose clips to eliminate olfactory cues. Tasting consisted of placing approximately 3.5 ml of olive oil in the mouth, holding it there for 3 seconds and then swallowing it in two aliquots so as to insure the throat would be stimulated. After 45 seconds passed, subjects were asked to rate the peak throat irritation sensitivity using the general labeled magnitude scale, a sensory scale developed to generate magnitude estimation-like quality data. Each subject was tested twice with all ten oils.
  • SOA was added to the corn oil (4 X 10 "4 , 1 X 10 "4 , 5 x 10 "5 M) to intensity match the irritation of the three levels of (-)-oleocanthal.
  • Subjects participated in two- alternative forced-choice (2 AFC) trials (four trials at every concentration for each subject) and in intensity ratings sessions (four ratings per each oil).
  • 2AFC trials subjects were presented with two 3.0 ml corn oil samples with matching intensities of SOA and (-)-oleocanthal in ascending order, and were required to sample oils as described above.
  • oleocanthal should mimic at least some of the pharmacological properties of ibuprofen, a potent modulator of inflammation.
  • COX cyclooxygenase
  • LO lipoxygenase
  • Ibuprofen is a potent COX-I and COX-2 inhibitor but does not inhibit lipoxygenase.
  • concentration dependence of oleocanthal for inhibition of ovine COX-I, human recombinant COX-2 and soybean 15 -lipoxygenase activities was measured using commercially available kits (Cayman Chemicals).
  • Indomethacin was used as a positive (inhibitory) control in the cyclooxygenase assays and nordihydroguaracetic acid (NDGA) and caffeic acid were used as positive (inhibitory) controls in the lipoxygenase assays.
  • Both enantiomers of oleocanthal exhibited a dose-dependent inhibition of both COX-I and COX-2 activities, with no effect on lipoxygenase activity, much as observed with ibuprofen (Table 1).
  • the calculated IC 50 (least squares regression analysis of inhibition vs. concentration) for oleocanthal (-) was 21.4 ⁇ m and 29.4 ⁇ m for COX-I and COX-2, respectively.
  • the IC 50 for oleocanthal (+) was 27.9 ⁇ m and 40.5 ⁇ m for COX-I and COX-2, respectively.
  • both enantiomers of oleocanthal were more potent at equimolar concentrations than ibuprofen in inhibiting COX-I and COX-2.
  • Both enantiomers of oleocanthal inhibited the peroxidation of serum lipids induced by metal ions in vitro to a similar degree as equimolar alpha-tocopherol (data not shown).
  • oleocanthal exhibits antioxidant activity comparable to alpha-tocopherol and has an arachidonic acid inhibitory profile (cyclooxygenase inhibition without lipoxygenase inhibition) indicating that both enantiomers of oleocanthal are classic NSAIDs, with potency superior to that of ibuprofen.
  • ibuprofen In addition to anti-inflammatory activity, ibuprofen has recently been shown to have a COX-independent ability to decrease the highly amyloidogenic AB42 peptide, perhaps accounting for epidemiologic evidence that Alzheimer's disease. Thus, it would be important to determine whether oleocanthal has similar activity.
  • a Structure Activity Relationship (SAR) Study may be conducted to determine the functional relative activities of oleocanthal derivatives to gain an understanding of the structural basis of oleocanthal irritation. As shown in Fig. 5, a compound having the structure:
  • Trigeminal ganglia were harvested from 1-3 day old Sprague-Dawley rat pups. Neurons were dissociated in Hanks Buffered Saline Solution (HBSS) with trypsin (0.0625%) for 15 minutes, collagenase (lmg/ml) and DNase (O.lmg/ml) for 45 minutes, and then were separated from myelin/debris using a 15/30/60% Percoll gradient. The neurons were plated on poly-1-lysine/laminin-coated coverslips in modified neurobasal medium supplemented with B27, lOOng/ml Nerve Growth Factor (NGF) and kept at 37°C, 5 % CO 2 .
  • HBSS Hanks Buffered Saline Solution
  • NEF Nerve Growth Factor
  • Oleocanthal activates rat trigeminal neurons; 5 microM of the olive oil irritant elicits a robust intracellular calcium increase in about 25 to about 35 % of cultured rat trigeminal neurons ( Figure 6). Therefore, to assess the irritation potency of oleocanthal analogs and in order to avoid human consumption of unnatural compounds, activity was determined by measurement of the intracellular calcium level in cultured rat trigeminal neurons. Analog structure and activity are summarized in Table 2. Analogs 5, 9, 10 and 12 did not elicit intracellular calcium increase in trigeminal neurons. Thus, both aldehyde groups, as well as unsaturation, are required to maintain full activity.
  • Analog 11 is of particular interest. Like oleocanthal, analog 11 (or 4-DHPEA- EDA) is a secoiridoid derivative naturally present in extra virgin olive oil.
  • Oleocanthal and A- DHPEA-EDA formation occurs during olive oil production by enzymatic and chemical degradation of their respective precursors ligstroside and oleuropein, two glucosylated secoiridoids abundantly synthesized in unripe olives (Figure 9).
  • Oleocanthal and 4-DHPEA- EDA are structurally very similar - the sole difference being a second phenolic hydroxyl group in 4-DHPEA-EDA.
  • 4-DHPEA-EDA has been reported to trigger very little oral irritation (Anke, H., et al., Planta Med. 1991; 57:344-346). In the present experiments, both molecules present a similar cellular activity, suggesting an equivalent ability to stimulate the sensory receptor.
  • the number of trigeminal neurons responding to oleocanthal was determined and defined as 100%.
  • the number of trigeminal neurons responding to analog 13 corresponded to approximately 6% (5 micromolar analog 13), 25 % (10 micromolar analog 13), 45% (20 micromolar analog 13) and 96% (50 micromolar analog 13) of the response to oleocanthal.
  • 18 - 20 trigeminal neurons were sensitive to oleocanthal.
  • Figure 8 shows is that at equi-molar concentrations, analog 13 is much less effective in stimulating trigeminal neurons compared with the reference, oleocanthal: It takes approximately 10 times the concentration of analog 13 to reach the potency of oleocanthal.
  • Analog 13 is very close in structure to oleocanthal (Table 2), lacking only a single carbon. The difference in trigeminal neuron activation by the compounds indicates that the binding site must be quite specific. While not wishing to be bound by any one theory, it is believed that the shorter chain of analog 13 pulls the rigid ring forward creating a steric obstruction to efficacious binding with the receptor.
  • Table 2 Structure, trigeminal neuron activation, and octanol-water partition (Log P) for oleocanthal and related analogs. Assessment of trigeminal neuron activation was based on relative responses to a single concentration (5 micromolar) of the analogs. The highest scale (+++) was assigned to the analogs that had approximately the same magnitude of response and excited the same number of neurons as oleocanthal. The + responses were weak but detectable and were observed in very few cells. ++ responses were assigned to analogs that elicited intermediate responses to an intermediated number of cells. No detectable response is indicated by O.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des analogues d'oléocanthal ainsi que des méthodes d'emploi d'oléocanthals dans diverses formules, y compris les additifs alimentaires; les produits pharmaceutiques; les produits cosmétiques; les produits de répulsion d'animaux; et des outils de découverte de gènes, de produits de gènes, d'allèles, de variants d'épissage, de variants de transcription, entre autres, concernant les récepteurs d'irritation chez les mammifères.
PCT/US2007/067393 2005-05-09 2007-04-25 Emploi de l'oléocanthal, principe irritant de l'huile d'olive, ainsi que de composés de structure et de fonction similaires Ceased WO2007133908A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/597,053 US8586632B2 (en) 2005-05-09 2007-04-25 Use of the irritating principal oleocanthal in olive oil, as well as structurally and functionally similar compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2006/017937 WO2006122128A2 (fr) 2005-05-09 2006-05-09 Utilisation d'oleocanthal principal d'irrigation dans l'huile d'olive et composants structuralement et fonctionnellement semblables
USPCT/US2006/017937 2006-05-09

Publications (2)

Publication Number Publication Date
WO2007133908A2 true WO2007133908A2 (fr) 2007-11-22
WO2007133908A3 WO2007133908A3 (fr) 2009-02-26

Family

ID=38694590

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/067393 Ceased WO2007133908A2 (fr) 2005-05-09 2007-04-25 Emploi de l'oléocanthal, principe irritant de l'huile d'olive, ainsi que de composés de structure et de fonction similaires

Country Status (1)

Country Link
WO (1) WO2007133908A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2918278A1 (fr) * 2007-07-04 2009-01-09 Girex Soc Par Actions Simplifi Utilisation de l'oleocanthal dans le traitement de l'inflammation cutanee.
US7879344B2 (en) * 2006-06-29 2011-02-01 Kimberly-Clark Worldwide, Inc. Transdermal delivery of oleocanthal for relief of inflammation
JP2013216628A (ja) * 2012-04-11 2013-10-24 Suntory Holdings Ltd 概日リズム調整剤
US8586632B2 (en) 2005-05-09 2013-11-19 Monell Chemical Senses Center Use of the irritating principal oleocanthal in olive oil, as well as structurally and functionally similar compounds
ES2769901A1 (es) * 2018-12-28 2020-06-29 Consejo Superior Investigacion Uso de secoiridoides para el tratamiento o la prevención de enfermedades inflamatorias inmunomediadas.
ES2769902A1 (es) * 2018-12-28 2020-06-29 Consejo Superior Investigacion Uso de secoiridoides para el tratamiento de la neuritis óptica.

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BEAUCHAMP ET AL: 'Phytochemistry: Ibuprofen-like activity in extra-virgin olive oil' NATURE vol. 437, no. 7055, 01 September 2005, pages 45 - 46 *
OWEN RW ET AL: 'Phenolic compounds and squalene in olive oils: the concentration and antioxidant potential of total phenols, simple phenols, secoiridoids, lignans and squalene' FOOD AND CHEMICAL TOXICOLOGY vol. 38, no. 8, 01 August 2000, pages 647 - 659 *
OWEN RW ET AL: 'The antioxidant/anticancer potential of phenolic compounds isolated from olive oil' EUROPEAN JOURNAL OF CANCER vol. 36, no. 10, 2000, OXFORD, GB, pages 1235 - 1247 *
SMITH ET AL: 'Synthesis and Assignment of Absolute Configuration of (-) -Oleocanthal: A Potent, Naturally Occurring Non-steroidal Anti-inflammatory and Anti-oxidant Agent Derived from Extra Virigen Olive Oils' ORGANIC LETTERS vol. 7, no. 22, 01 January 2005, COLOMBUS, OHIO, USA, pages 5075 - 5078 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8586632B2 (en) 2005-05-09 2013-11-19 Monell Chemical Senses Center Use of the irritating principal oleocanthal in olive oil, as well as structurally and functionally similar compounds
US7879344B2 (en) * 2006-06-29 2011-02-01 Kimberly-Clark Worldwide, Inc. Transdermal delivery of oleocanthal for relief of inflammation
FR2918278A1 (fr) * 2007-07-04 2009-01-09 Girex Soc Par Actions Simplifi Utilisation de l'oleocanthal dans le traitement de l'inflammation cutanee.
WO2009024680A1 (fr) * 2007-07-04 2009-02-26 B.C. Development S.A. Utilisation de l'oleocanthal dans le traitement de l'inflammation cutannee
JP2013216628A (ja) * 2012-04-11 2013-10-24 Suntory Holdings Ltd 概日リズム調整剤
ES2769901A1 (es) * 2018-12-28 2020-06-29 Consejo Superior Investigacion Uso de secoiridoides para el tratamiento o la prevención de enfermedades inflamatorias inmunomediadas.
ES2769902A1 (es) * 2018-12-28 2020-06-29 Consejo Superior Investigacion Uso de secoiridoides para el tratamiento de la neuritis óptica.

Also Published As

Publication number Publication date
WO2007133908A3 (fr) 2009-02-26

Similar Documents

Publication Publication Date Title
US8586632B2 (en) Use of the irritating principal oleocanthal in olive oil, as well as structurally and functionally similar compounds
EP2641891B1 (fr) ACTIVATEUR DE PKC-epsilon
Tiroch et al. Bitter sensing TAS2R50 mediates the trans-resveratrol-induced anti-inflammatory effect on interleukin 6 release in HGF-1 cells in culture
WO2007133908A2 (fr) Emploi de l'oléocanthal, principe irritant de l'huile d'olive, ainsi que de composés de structure et de fonction similaires
KR20190044647A (ko) 신경변성 질환과 관련된 신경-염증에서 대식세포/미세아교세포
JP2022520518A (ja) パンテテイン誘導体及びその使用
KR20110133568A (ko) 2고리성 γ-아미노산 유도체의 제조 방법
KR20240008882A (ko) 약학적 활성 화합물로서 레조르시놀 유도체 및 이의 제조방법
CN105682688A (zh) Rett综合征及其治疗
WO2007041440A2 (fr) Effets anti-inflammatoires de la neuroprotectine d1/protectine d1 et de ses stereoisomeres naturels
JP6517833B2 (ja) 神経変性疾患の処置に有用なウィザノライド
US8541435B2 (en) Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of Alzheimer's disease (AD)
WO2017192599A1 (fr) Traitement des infections provoquées par le virus zika à l'aide d'inhibiteurs d'alpha-glucosidase
CN113891711B (zh) 用于治疗神经退行性疾病的化合物
CN109415356A (zh) 4-(5-(4,7-二甲基苯并呋喃-2-基)-1,2,4-噁二唑-3-基)苯甲酸的结晶形式及其制备方法
WO2017066103A1 (fr) Nouveaux composés bénéfiques dans le traitement de maladies et de troubles du système nerveux central
US12486218B2 (en) Compounds advantageous in the treatment of central nervous system diseases and disorders
US20240239739A1 (en) Compounds advantageous in the treatment of central nervous system diseases and disorders
US20160137592A1 (en) Novel compounds advantageous in the treatment of central nervous system diseases and disorders
EP3122363B1 (fr) Carbamates de galantamine pour le traitement de l'autisme
US20120122822A1 (en) Compositions for reducing beta-amyloid-induced neurotoxicity comprising beta-secretase inhibitor
CN111671755A (zh) 用于治疗神经退行性疾病的化合物
US20230355625A1 (en) Methods of treatment
FR2878522A1 (fr) Nouveaux inhibiteurs specifiques de la caspas-10
WO2014162106A1 (fr) Nouveaux derives de chalcone presentant une activite anti-allergique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07761264

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase

Ref document number: 07761264

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 12597053

Country of ref document: US